Editas Medicine Inc. (EDIT)
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology.
The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia.
In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease.
It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Country | United States |
IPO Date | Feb 3, 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 246 |
CEO | Dr. Gilmore O'Neill M.D. |
Contact Details
Address: 11 Hurley Street Cambridge, Massachusetts United States | |
Website | https://www.editasmedicine.com |
Stock Details
Ticker Symbol | EDIT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001650664 |
CUSIP Number | 28106W103 |
ISIN Number | US28106W1036 |
Employer ID | 46-4097528 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Gilmore O'Neill M.D. | President, Chief Executive Officer & Director |
Amy Parison | Senior Vice President & Chief Financial Officer |
Cristi Barnett | Senior Vice President of Corporate Communications & Investor Relations |
Damien Grierson J.D. | Senior Vice President, Head of Legal & Corporate Secretary |
Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member |
Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member |
Dr. Linda C. Burkly Ph.D. | Executive Vice President & Chief Scientific Officer |
Frank Panaccio | Senior Vice President & Head of Business Development |
Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer |
Linea Aspesi | Executive Vice President & Chief Administration Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 15, 2025 | ARS | Filing |
Apr 15, 2025 | DEFA14A | Filing |
Apr 15, 2025 | DEF 14A | Filing |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 3 | Filing |
Apr 04, 2025 | PRE 14A | Filing |
Mar 27, 2025 | 4 | Filing |
Mar 27, 2025 | 4 | Filing |
Mar 27, 2025 | 4 | Filing |